While previous studies have demonstrated an enhanced capacity for expansion and therapeutic efficacy of CD4+ T cells primed in the presence of IL-7 or expressing a constitutively active mutant of STAT5 (refs. 44,45), our study extends these findings by demonstrating that IL-7/IL-15-treated CD4+ T cells adopt a unique surface phenotype in vitro associated with TSCM-like cells, which has mainly described in the context of tumor-specific CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.